Immunome
Update in progressIMNM (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Immunome, Inc. is a biotechnology company focused on discovering and developing antibody-based therapies for cancer. It works on antibody-drug conjugates and other oncology treatments in the United States. Its clinical assets include Varegacestat, a gamma secretase inhibitor in Phase 3 for desmoid tumors, and IM-1021, a ROR1-targeted ADC in Phase 1. Preclinical programs include IM-3050 (FAP radioligand therapy) and solid-tumor ADCs IM-1617, IM-1340, and IM-1335. Based in Bothell, Washington, and founded in 2006.
Company score
- Sentiment
- 0.50
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.23
- Governance
- 0.08
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.08
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.29
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!